* denotes a publication that resulted from CTD2 intra-Network collaborations
Fred Hutchinson CTD2 researchers identified novel therapeutic targets for precision oncology using high-throughput functional phenotyping with siRNA and drug libraries in primary patient derived head and neck cancer cells.
CTD2 scientists at Fred Hutchinson showed that the triplet combination of WEE1 tyrosine kinase inhibitor AZD1775, cisplatin, and docetaxel is safe, tolerable, and effective in a phase I clinical trial of head and neck cancer.
Scientists proposed a framework to investigate the genomic alterations in neuroblastoma subtypes and identified, TEAD4, a transcription factor as a novel target for therapy.
CTD2 scientists at Emory University developed a high-throughput time-resolved fluorescence resonance energy transfer assay to discover small-molecule inhibitors of receptor binding protein, NSD3 protein-protein interactions.
CSHL CTD2 scientists developed a method that allows temporal control of CRISPR/Cas9 by conjugating a destabilizing domain to Cas9. This robust high-throughput approach can be used for gene editing and to investigate interactions between functional genes.
Review of methods with a focus on chemical-genetic screens used in the identification of the mechanisms of action of small molecules.
CTD2 scientists at UCSF (1) identified two major subtypes of KRAS mutant cancers of the lung, pancreas, and the large intestine which differentially engage effector pathways. These findings can be used to develop effective combination of therapies.
Researchers at UCSF (2) discovered that antisecretory factor decreases osmotic adaptation, increases drug uptake, and promotes anti-tumor activity in glioblastoma.
Studies demonstrated that epithelial-to-mesenchymal transition-inducing transcription factor, Snail, represses tumor suppressive RNA splicing regulatory protein, ESRP1, and promotes tumorigenesis in lung cancer.